101BHG D01
Alternative Names: 101BHG-D01Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Beijing Shuobai Pharmaceutical Technology
- Class Antirheumatics; Antisecretories
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Rhinorrhoea
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in China (Inhalation, Aerosol)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Rhinorrhoea(In volunteers) in China (Inhalation, Aerosol)
- 16 Apr 2022 Pharmacokinetic and adverse events data from a phase I trial in Rhinorrhoea released by Beijing Shuobai Pharmaceutical Technology